metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population
versus ipilimumab alone
	pembrolizumab (10mg/kg) 2 weeks vs. ipilimumab alone	1	-735 [-1562; 92] /10000 122/279 vs. 142/278	NaN [NaN; NaN] /10000 0/0 vs. 0/0	-